Raymond James Downgrades Editas Medicine (EDIT) to Market Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
Go back to Raymond James Downgrades Editas Medicine (EDIT) to Market Perform
November 5, 2024 4:19 PM EST
Chardan Capital Markets analyst Geulah Livshits reiterated a Buy rating and $12.00 price target on Editas Medicine (NASDAQ: EDIT).
The analyst comments "EDIT (Buy, PT $12): 3Q24 Results; Reni-cel Data at ASH; In Vivo Updates in 1Q25. On 4 November, Editas Medicine reported 3Q24 results and... More
November 5, 2024 5:23 AM EST
Barclays analyst Gena Wang lowered the price target on Editas Medicine (NASDAQ: EDIT) to $5.00 (from $7.00) while maintaining a Equalweight rating.
The analyst comments "Key takeaways. 3Q24 PR was incremental following recent strategic update (see EDIT - Strategic update mixed, 10/22/2024). Reni-cel (EDIT-301): Mgmt. reiterated... More
November 4, 2024 12:25 PM EST
Truist Securities analyst Joon Lee lowered the price target on Editas Medicine (NASDAQ: EDIT) to $8.00 (from $12.00) while maintaining a Buy rating.
The analyst comments "3Q24: No surprises on the quarter post recent announcements (our prior takes - HERE and HERE). EDIT... More
